A Real-World Multicenter Retrospective Observational Study on Polish Experience with Nintedanib Therapy in Patients with Idiopathic Pulmonary Fibrosis: The PolExNIB Study

A Real-World Multicenter Retrospective Observational Study on Polish Experience with Nintedanib Therapy in Patients with Idiopathic Pulmonary Fibrosis: The PolExNIB Study

Nintedanib is a disease-modifying agent licensed for the treatment of IPF. Data on Polish experience with nintedanib in IPF are lacking. The present study aimed to describe the safety and efficacy profiles of nintedanib in a large real-world cohort of Polish patients with IPF. This was a multicenter...

Full description

Bibliographic Details
Main Authors: Sebastian Majewski, Adam J. Białas, Adam Barczyk, Halina Batura-Gabryel, Małgorzata Buchczyk, Anna Doboszyńska, Katarzyna Górska, Luiza Grabowska-Skudlarz, Hanna Jagielska-Len, Agnieszka Jarzemska, Ewa Jassem, Dariusz Jastrzębski, Aleksander Kania, Marek Koprowski, Michał Krawczyk, Rafał Krenke, Katarzyna Lewandowska, Barbara Mackiewicz, Magdalena M. Martusewicz-Boros, Janusz Milanowski, Małgorzata Noceń-Piskorowska, Agata Nowicka, Kazimierz Roszkowski-Śliż, Alicja Siemińska, Krzysztof Sładek, Małgorzata Sobiecka, Tomasz Stachura, Małgorzata Tomczak, Witold Tomkowski, Marzena Trzaska-Sobczak, Dariusz Ziora, Beata Żołnowska, Wojciech J. Piotrowski
Format: Article
Language:English
Published: MDPI AG 2023-07-01
Series:Journal of Clinical Medicine
Subjects:
nintedanib
idiopathic pulmonary fibrosis (IPF)
real-world data
efficacy
safety
Poland
Online Access:https://www.mdpi.com/2077-0383/12/14/4635

Internet

https://www.mdpi.com/2077-0383/12/14/4635

Similar Items